DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Company Overview - DIMERx, Inc. is a late-stage clinical biopharmaceutical company focused on developing covalently bonded dimer therapeutics [1][5] - The company is pioneering a proprietary dimer technology platform to create novel chemical entities for high-impact, underserved medical conditions [5] Leadership Appointment - Sergio Traversa, PharmD, has been appointed as an Independent Director to the Board of Directors, effective June 25, 2025 [1] - Dr. Traversa is currently the CEO of Relmada Therapeutics and has extensive experience in the healthcare sector, including senior roles at Eli Lilly and Johnson & Johnson [2][4] Strategic Importance - The appointment of Dr. Traversa is seen as critical for DIMERx's growth, especially with support from the NIH HEAL Initiative and momentum in clinical programs [3] - Dr. Traversa emphasizes the urgent need for innovative solutions in chronic pain management, aligning with public health priorities [3] Product Development - DIMERx's lead asset, DMX-101, is in phase 2 clinical development for chronic lower back pain and has shown a favorable safety profile and analgesic benefits in over 400 human subjects [6] - The second program, DMX-201, is being developed for conditions involving endothelial dysfunction, such as vaso-occlusive crisis pain in sickle cell disease [7] Collaboration and Research Initiatives - DIMERx collaborates closely on clinical strategy with Maurizio Fava, MD, Chair of the Mass General Brigham Academic Medical Centers Psychiatry Department [5] - The NIH HEAL Initiative aims to accelerate research to address the opioid overdose crisis and chronic pain, which aligns with DIMERx's mission [8]